Stanford Rook slumps 70% as TB product fails trials

More than 70 per cent was wiped from the value of the biotechnology company Stanford Rook yesterday after its main product failed clinical trials for the treatment of tuberculosis.

Shares in Stanford Rook crashed by 390p to 150p, reducing the value of the company from pounds 104m to pounds 29m, after the company announced that it had been forced to abandon plans to market its one drug, SRL172, as a treatment for tuberculosis.

Trials in South Africa involving 347 patients found that the drug, which works by triggering the immune system, was no more effective in treating tuberculosis than existing therapies.

The results are a serious setback for the company and mean that SRL172 will not come to market until 2002 at the earliest. Stanford Rook had expected the drug to start earning revenues as early as next year as a treatment for tuberculosis, which causes three million deaths a year. Analysts had expected this form of treatment to generate as much as pounds 300m in sales.

The setback makes Stanford Rook the latest in a long line of biotechnology companies to shock the market. Founded in 1992, it obtained a listing on the Alternative Investment Market in July, 1995, since when the shares have shot up from just over pounds 1 to a high of 635p. In the week before the South African trial results were released the shares rose 19 per cent in the expectation that they would be positive.

The news comes just three weeks after another "biobabe", Bicompatibles International, stunned investors by disclosing that a marketing deal for its main product with Johnson & Johnson, had collapsed.

Eric Boyle, executive chairman of Stanford Rook put a brave face on the trial results saying that although it was disappointed, the treatment of TB would, in fact, have been the smallest market for the drug.

He said the company was now pressing ahead with the development of SRL172 as a treatment for melanoma or skin cancer, hay fever, asthma and aids. The cancer treatment market is estimated to be worth up to pounds 1bn.

Phase three trials - the final set of clinical tests before a drug goes on the market - of SRL172 as a cancer treatment are due to begin the first half of next year and will take two years to complete. Second- phase trials for its use as a treatment for hayfever and asthma are in preparation in Oxford and Southampton.

However, none of these treatments will be ready to go on to the market until the next century, always supposing they get through clinical trials.

The principal outside shareholder is Bank Von Ernst, a private Swiss bank owned by the German retail bank Bayerische Vereinsbank, which owns a 24.9 per cent stake. Yesterday it saw the value of its holding plummet from pounds 26m to pounds 7m. A spokesman said the shares were held on behalf of private clients but could not comment further.

Start your day with The Independent, sign up for daily news emails
ebooks
ebooksAn introduction to the ground rules of British democracy
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Recruitment Genius: Mortgage Advisor - OTE £95,000

£40000 - £95000 per annum: Recruitment Genius: This is an exciting opportunity...

SThree: Trainee Recruitment Consultant

competitive: SThree: Are you passionate about sales?Do you have a keen interes...

Recruitment Genius: Loan Adviser - OTE £30,000

£17000 - £30000 per annum: Recruitment Genius: This is an exciting opportunity...

Recruitment Genius: Sales Assistant / Buyer

£15000 - £17000 per annum: Recruitment Genius: This company offers a range of ...

Day In a Page

Greece debt crisis: EU 'family' needs to forgive rather than punish an impoverished state

EU 'family' needs to forgive rather than punish an impoverished state

An outbreak of malaria in Greece four years ago helps us understand the crisis, says Robert Fisk
Gaza, a year on from Operation Protective Edge: The traumatised kibbutz on Israel's front line, still recovering from last summer's war with Hamas

Gaza, a year on from Operation Protective Edge

The traumatised kibbutz on Israel's front line, still recovering from last summer's war with Hamas
How to survive electrical storms: What are the chances of being hit by lightning?

Heavy weather

What are the chances of being hit by lightning?
World Bodypainting Festival 2015: Bizarre and brilliant photos celebrate 'the body as art'

World Bodypainting Festival 2015

Bizarre and brilliant photos celebrate 'the body as art'
alt-j: A private jet, a Mercury Prize and Latitude headliners

Don't call us nerds

Craig Mclean meets alt-j - the math-folk act who are flying high
How to find gold: The Californian badlands, digging out crevasses and sifting sludge

How to find gold

Steve Boggan finds himself in the Californian badlands, digging out crevasses and sifting sludge
Singing accents: From Herman's Hermits and David Bowie to Alesha Dixon

Not born in the USA

Lay off Alesha Dixon: songs sound better in US accents, even our national anthem
10 best balsamic vinegars

10 best balsamic vinegars

Drizzle it over salad, enjoy it with ciabatta, marinate vegetables, or use it to add depth to a sauce - this versatile staple is a cook's best friend
Wimbledon 2015: Brief glimpses of the old Venus but Williams sisters' epic wars belong to history

Brief glimpses of the old Venus but Williams sisters' epic wars belong to history

Serena dispatched her elder sister 6-4, 6-3 in eight minutes more than an hour
Greece says 'No': A night of huge celebrations in Athens as voters decisively back Tsipras and his anti-austerity stance in historic referendum

Greece referendum

Greeks say 'No' to austerity and plunge Europe into crisis
Ten years after the 7/7 terror attacks, is Britain an altered state?

7/7 bombings anniversary

Ten years after the terror attacks, is Britain an altered state?
Beautiful evening dresses are some of the loveliest Donatella has created

Versace haute couture review

Beautiful evening dresses are some of the loveliest Donatella has ever created
No hope and no jobs, so Gaza's young risk their lives, climb the fence and run for it

No hope and no jobs in Gaza

So the young risk their lives and run for it
Fashion apps: Retailers roll together shopping and social networking for mobile customers

Fashion apps

Retailers roll together shopping and social networking for mobile customers
The Greek referendum exposes a gaping hole at the heart of the European Union – its distinct lack of any genuine popular legitimacy

Gaping hole at the heart of the European Union

Treatment of Greece has shown up a lack of genuine legitimacy